| Human splicing diversity and the extent of unannotated splice junctions across human RNA-seq samples on the Sequence Read Archive A Nellore, AE Jaffe, JP Fortin, J Alquicira-Hernández, L Collado-Torres, ... Genome biology 17, 1-14, 2016 | 123 | 2016 |
| Methods for correcting inference based on outcomes predicted by machine learning S Wang, TH McCormick, JT Leek Proceedings of the National Academy of Sciences 117 (48), 30266-30275, 2020 | 56 | 2020 |
| Post-prediction Inference S Wang, TH McCormick, JT Leek bioRxiv, https://doi.org/10.1101/2020.01.21.914002, 2020 | 53* | 2020 |
| Waveline-001: updated results from a phase 1 dose escalation and cohort expansion study of zilovertamab vedotin (MK-2140) in non-Hodgkin lymphoma SE Spurgeon, M Mei, PM Barr, JC Barrientos, S de Vos, RR Furman, ... Blood 140 (Supplement 1), 6640-6641, 2022 | 10 | 2022 |
| Linking open-source code commits and MOOC grades to evaluate massive online open peer review S Wang, LR Jager, K Kammers, A Hadavand, JT Leek arXiv, arXiv:2104.12555, 2021 | 4 | 2021 |
| Zilovertamab vedotin (MK‐2140) in relapsed or refractory (R/R) non‐Hodgkin lymphoma (NHL): 14‐month follow‐up of the phase 1 waveLINE‐001 study ML Wang, M Mei, PM Barr, JC Barrientos, S de Vos, RR Furman, K Patel, ... Hematological Oncology 41, 571-572, 2023 | 1 | 2023 |
| Postprediction inference for clinical characteristics extracted with machine learning on electronic health records A Sondhi, AS Rich, S Wang, JT Leek JCO Clinical Cancer Informatics 7, e2200174, 2023 | 1 | 2023 |
| waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated … D Lavie, M Ozcan, E Paszkiewicz-Kozik, E González Barca, TM Kim, ... Journal of Clinical Oncology 41 (16_suppl), TPS7589-TPS7589, 2023 | | 2023 |
| r2rtf–an R Package to Produce Rich Text Format (RTF) Tables and Figures S Wang, S Ye, KM Anderson, Y Zhang PharmaSUG, 2020 | | 2020 |
Jeff LeekChief Data Officer, VP, and J Orin Edson Foundation Professor, Fred Hutchinson Cancer CenterVerified email at fredhutch.org
